What factors will most influence your decision to offer ENCELTO to patients with macular telangiectasia type 2?

Yet another (presumably very expensive) surgical treatment for a chronic macular disease was approved on the basis of OCT measurements without demonstrating visual benefit to the patient in a disease with a slow, variable course.

Show me quality of life studies and visual benefit justifying surgical risk and unknown long-term complications. Show me how the cost has a greater societal benefit than addressing preventable blindness, not being addressed for lack of resources.

Love the science though...